Nature Reviews Neurology

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	574
Lymphatic propagation of α-synuclein	365
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	354
Brain stimulation aids walking after spinal injury	324
ANA2025 marks important milestones for the ANA and NINDS	263
Refining oxytocin therapy for autism: context is key	260
Reply to ‘Perils and pitfalls of near-death experience research’	249
Neural cell state shifts and fate loss in ageing and age-related diseases	248
Ventricular enlargement caused by aducanumab	235
Microglia, spreaders of Aβ seeds	234
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	232
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	230
Global synergistic actions to improve brain health for human development	226
NODDI reveals brain microstructural changes in multiple sclerosis	216
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	211
Disease-specific modifications of tau protein	172
Continuous levodopa production by an artificial enzyme	168
TREM2 mediates phagocytosis in glioblastoma	157
Study reveals new ALS risk genes	146
SEQUINS — a new initiative to address disparities in neurology	145
Nir Giladi (1955–2024)	144
Spinal muscular atrophy treatment in utero	142
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	141
Mitochondrial DNA instability in Huntington disease	117
The Digitized Memory Clinic	117

Imperatives and co-benefits of research into climate change and neurological disease	113
The impact of rare genetic variants on Alzheimer disease	113
The role of the gut microbiota in multiple sclerosis	110
Psychosis-causing lesions mapped to a hippocampal circuit	108
Implications of AD plasma and PET biomarker discordance	107
Neuroinflammation predicts cognitive decline in FTD	107
Ultrasound lets gene therapy into the brain	105
Menopause influences tau pathology	101
Role for endogenous retrovirus in FTD	100
Brain volume is associated with cognition in MS	99
Amyloid plaques: hotspots for microglial turnover	98
MRI-based deep learning for TLE diagnosis	91
Challenges of combining multimodal data in assessment of people with traumatic brain injury	91
Diversity, equity and inclusion in neurology	90
Gene therapy for seizures in focal cortical dysplasia	88
Author Correction: Viral pathogens increase risk of neurodegenerative disease	87
Precision neuroimmunology in multiple sclerosis — the horizon is near	80
First trials test targeting of α-synuclein for Parkinson disease	80
Parkinson disease pathology can originate in the kidney	78
Neurological care for LGBT+ people	74
The challenges of anti-tau therapeutics in Alzheimer disease	74
Management of freezing of gait — mechanism-based practical recommendations	73
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	72
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	70
α-Synuclein pathology as a target in neurodegenerative diseases	65
Food is brain medicine — relevance and translation to neurology	65
Neurosteroids alleviate seizures in rats	65
Glymphatic dysfunction in PD clinical progression	62
A new biological classification for Parkinson disease	61
Ultrasound ablation treatment for PD	61
Evidence for altered astrocyte function in Duchenne muscular dystrophy	61
Addressing disparities in neurology by building the workforce in LMICs	61
Thalamic inflammation — a therapeutic target for brain injury?	57
Exosomal microRNA is promising biomarker in PD	56
Coeliac disease as a model for understanding multiple sclerosis	55
New IDEAS about amyloid, race and dementia disparities	55
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	55
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	54
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	53
Spinal cord stimulation for the treatment of chronic pain	51
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	51
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	50
From the prodromal stage of multiple sclerosis to disease prevention	47
Is Alzheimer disease a disease?	47
The role of glial cells in multiple sclerosis disease progression	46
Synaptic degeneration in Alzheimer disease	45
The global and regional burden of diabetic peripheral neuropathy	45
X-chromosome variants and PD in Latin America	45
Oligomeric tau could spread through synapses in AD	45

Neurofilament light chain induces neuroinflammation	44
Hypothyroidism is associated with dementia risk	44
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	44
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	44
Neurology in 2025 — reflections from Africa	43
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	43
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	42
Global epidemiology of migraine and its implications for public health and health policy	41
The inter-relationship between delirium and dementia: the importance of delirium prevention	41
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	40
α-Synuclein seeds in amyotrophic lateral sclerosis	40
Risk locus for paediatric astrocytoma identified	40
Dual function of biomolecular condensates	40
Moving towards meaningful patient and public engagement	40
Huntington disease-like 2: insight into neurodegeneration from an African disease	39
Prognostic plasma biomarkers for spinal cord injury	38
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	37
Change in stroke outcomes over 20 years	36
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
Origins and immunopathogenesis of autoimmune central nervous system disorders	35
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	34
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	33
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	31
New developments in guidelines for brain death/death by neurological criteria	29
CAR T cells offer hope in glioblastoma	28
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	28
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	27
Neurology in 2025 — reflections from the USA	27
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	26
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	26
High rate of epilepsy in young individuals who died with COVID-19	25
Serum NfL as an MS biomarker	24
John Q. Trojanowski	24
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Does antiherpetic antiviral therapy reduce the risk of dementia?	24
ALS pathogenesis linked to actin barrier collapse	23
Aberrant protein networks in Alzheimer disease	23
BCAS1+ oligodendrocytes aid remyelination in MS	22
AI aces diagnosis of chronic ataxias	21
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	20
Author Correction: The complex aetiology of cerebral palsy	20
Charting brain development across the human lifespan	20
Pharmacological rehabilitation for stroke	20
AI and protein structure and function in neurological disease: relevance to disease management	19
The murky waters of sex differences in post-stroke cognitive impairment	19
Neuroprognostication: a conceptual framework	18
Addressing disparities in the global epidemiology of stroke	18
Pathogenetic mechanisms and treatment targets in cerebral malaria	17
Genome-wide analysis furthers decoding of Alzheimer disease genetics	16
Alzheimer disease in African American individuals: increased incidence or not enough data?	16
Molecular biomarkers for vascular cognitive impairment and dementia	15
Effects of diet on MS onset and course	15
Clocking the age of Parkinson disease onset	15
Nusinersen treatment response markers	14
Predictive tools in psychosis: what is ‘good enough’?	14
Altered muscle cholesterol transport in ALS	14
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	14
Advancing multiple sclerosis management in older adults	13
From adaptive deep brain stimulation to adaptive circuit targeting	13
Nanoprobe for blood–brain barrier changes	13
Markers help to predict dementia with Lewy bodies	12
Alzheimer disease seen through the lens of sex and gender	12
Sex and gender in neurodevelopmental conditions	12
Mechanistic insights into the interaction between epilepsy and sleep	12
Multidimensional MRI detects astrogliosis	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Shared glial pathology in HD and schizophrenia	11
Advances in the therapeutic algorithm for myasthenia gravis	11
Parkinson disease pathology in inflammatory bowel disease	11
Alzheimer disease in Down syndrome linked to APOE	10
Walking the Talk for Dementia — an experience to break down barriers	10
Timing of hormone replacement therapy could influence Alzheimer disease risk	10
Author Correction: Why functional neurological disorder is not feigning or malingering	10
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	10
Limitations of neurocentric models for near-death experiences	10
Evidence-based clinical care and policy making for schizophrenia	9
Immune mechanisms and shared immune targets in neurodegenerative diseases	9
Psychiatric sequelae of traumatic brain injury — future directions in research	9
Artificial intelligence in epilepsy — applications and pathways to the clinic	9

Inclusion in neurological research: empowering people living with neurological diseases	9
Multisite chronic pain: a risk factor for dementia	9
Vulnerable dopamine neurons identified	8
PD pathology spread linked to mtDNA damage	8
Embodiment of structural racism and multiple sclerosis risk and outcomes in the USA	8
A global view of the genetic basis of Alzheimer disease	8
MS drug beneficial in an underrepresented group	8
Ageing reduces potential for remyelination in multiple sclerosis	8
Peripheral B cells altered in Parkinson disease	8
Seizure-associated changes in the Golgi apparatus	8
T cell–microbiome communication influences disease in MS model	8
27-Hydroxycholesterol propagates α-synuclein pathology in Parkinson disease	8
Identification of neurons involved in schizophrenia	8
Glymphatic dysfunction detected in bvFTD	7
Review and update of the concept of embolic stroke of undetermined source	7
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications	7
Novel oxytocin spray is beneficial in ASD	7
Early-stage Alzheimer disease: getting trial-ready	7
Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets	7
Sensory feedback in upper limb prosthetics: advances and challenges	7
Recycling brain scans with AI	7
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic	7
Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums	6
Oestrogen receptor variants linked to AD traits	6
Addressing disparities in neurology by enhancing inclusive practice	6
Addressing multiple sclerosis disparities in Latin American and other populations	6
Dementia risk scores in diverse populations	6
Breakthrough technology restores function after complete paralysis	6
Astrocytes in the initiation and progression of epilepsy	6
From precision diagnosis to precision treatment in epilepsy	6
Multifaceted roles of APOE in Alzheimer disease	6
Calcium dysregulation could underlie lysosomal impairment in AD	6
BTK inhibitor falters in multiple sclerosis trials	6
Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis	5
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics	5
EBV-specific T cells in multiple sclerosis	5
Oligodendrocyte progenitor cell transplant for MS	5
New CRISPR-based strategies for Alzheimer disease	5
Implications of immunometabolism for smouldering MS pathology and therapy	5
Functional brain networks in the evaluation of patients with neurodegenerative disorders	5
Monitoring disease onset in amyotrophic lateral sclerosis	5
Brain–machine interface treats pain in rats	5
Engineered TREM2 antibody clears Aβ in mice	5
Translating lifestyle interventions for optimal brain health in Africa	5
Stem cells show promise in Parkinson disease	5
Publisher Correction: Microglial transcriptomics meets genetics: new disease leads	5
Microglial senescence is a potential therapeutic target for Alzheimer disease	5
Skin α-synuclein differentiates synucleinopathies	4
GluA2 modulator targets excitotoxicity in MS	4
‘On-demand’ gene therapy for epilepsy	4
Pathogenic autoantibodies in multiple sclerosis — from a simple idea to a complex concept	4
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?	4
Closing the loop for patients with Parkinson disease: where are we?	4
Identifying molecular targets in trigeminal nociception	4
A biomarker for mild cognitive impairment	4
Finger-prick blood test for Alzheimer disease	4
Neurology under the midnight sun: EAN Congress 2024 comes to Helsinki	4
Neuroimmune, metabolic and oxidative stress pathways in major depressive disorder	4
Sleep and circadian disturbances in children with neurodevelopmental disorders	4
Reply to: Questioning the cycad theory of Kii ALS–PDC causation	4
Women’s neurology: a growing subspeciality to tackle sex and gender disparities	4
Addressing disparities in neurology by identifying gaps in hospital care	4
Novel plasma markers for Parkinson disease	4
Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms	4
The importance of getting evidence into practice	3
Epidemiology and characteristics of multiple sclerosis in Latin America	3
Neuropsychology’s race problem does not begin or end with demographically adjusted norms	3
Bruton tyrosine kinase inhibitors for multiple sclerosis	3
Glioblastomas divert glucose to promote growth	3
White matter hyperintensities — location matters	3
The changing landscape of primary autoimmune neuropathies	3
Lecanemab trial in AD brings hope but requires greater clarity	3
Epstein–Barr virus and MS — a causal link	3
Exome sequencing identifies risk variants for AD	3
Disentangling clinical and biological trajectories of neurodegenerative diseases	3
Exosomal microRNAs may aid differential diagnosis of movement disorders	3
Epigenetic clocks and DNA methylation biomarkers of brain health and disease	3
Advances in PET imaging of protein aggregates associated with neurodegenerative disease	3
Spreading depolarization as a therapeutic target in migraine	3
Autoimmune encephalitis-associated epilepsy	3
Why functional neurological disorder is not feigning or malingering	3
New local therapy strategies for brain tumours	3
WNT receptor variant linked to synaptic degeneration	3
Insights into the toxic effects of mutant huntingtin	3
Environmental–genetic interactions in ageing and dementia across Latin America	3
MS drug alters B cell metabolism	3
FSH provides link between menopause and AD	3
Pro-inflammatory diet is linked to dementia risk	3
Microglial phagocytosis in Alzheimer disease	3
A tale of race and B cells in multiple sclerosis	3
Glioblastoma tackled with oncolytic virus	3
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits	2
Rubella virus might increase risk of MS	2
Transcriptomic mapping of the human cerebrovasculature	2
TREM2 response occurs early in amyloid cascade	2